Home › Funds › TWO SIGMA ADVISERS, LP › ALNY

TWO SIGMA ADVISERS, LP position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

TWO SIGMA ADVISERS, LP reported holding 1,132,560 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q4 2025 13F filing — a position valued at US$450.4M, representing 0.88% of its reported portfolio and ranking #25 among its reported holdings. TWO SIGMA ADVISERS, LP has disclosed ALNY holdings in 9 of the last 10 reported quarters, going back to Q3 2023.

Latest position (Q4 2025)1.13M sh
Reported value held$450.36M
Portfolio Weight0.88%
First reportedQ3 2023
Last changeAdd
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How TWO SIGMA ADVISERS, LP's ALNY position evolved

TWO SIGMA ADVISERS, LP first disclosed a stake in ALNY in Q3 2023 at 35,900 shares (US$6.4M). The position peaked in Q4 2025 at 1,132,560 shares, worth US$450.4M. Across 9 filings, TWO SIGMA ADVISERS, LP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q4 2025) shows 1,132,560 shares valued at US$450.4M — an increase of 240,060 shares quarter over quarter.. Notable position changes include a 60% trim in Q3 2024 (shares fell 14% over the following quarter), a 250% increase in Q1 2025 (shares rose 20% over the following quarter), a 235% increase in Q3 2025 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 35.90K $6.36M New
Q1 2024 189.60K $28.34M New
Q2 2024 258.70K $62.86M Add
Q3 2024 103.10K $28.36M Reduce
Q4 2024 78.80K $18.54M Reduce
Q1 2025 275.80K $74.47M Add
Q2 2025 266.10K $86.77M Reduce
Q3 2025 892.50K $406.98M Add
Q4 2025 1.13M $450.36M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 35 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has TWO SIGMA ADVISERS, LP held ALNY?

TWO SIGMA ADVISERS, LP has disclosed ALNY holdings in 9 of the last 10 reported quarters, going back to Q3 2023.

What is TWO SIGMA ADVISERS, LP's current position in ALNY?

As of Q4 2025, TWO SIGMA ADVISERS, LP holds 1.13M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $450.36M, representing 0.88% of its reported portfolio and ranking #25.

Has TWO SIGMA ADVISERS, LP been buying or selling ALNY?

In the latest 13F filing (Q4 2025), TWO SIGMA ADVISERS, LP increased its position in ALNY. The position peaked in Q4 2025 at 1.13M shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.